Press Release
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
NEW YORK and TOKYO, March 16, 2021 /PRNewswire/ -- Perception Neuroscience (Perception), an atai Life Sciences (atai) company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd. (Otsuka), announce a collaboration and licensing agreement for
Press Release
IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation
SAINT LAURENT, Quebec, and NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX ) (OTCQB:IGXT) (the “ Corporation ”) today announced that its wholly owned subsidiary, IntelGenx Corp. (“ IntelGenx ”), a leader in pharmaceutical films, has agreed to the terms of a
Press Release
DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK
NEW YORK, March 10, 2021 /PRNewswire/ -- DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency
Press Release
atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round
NEW YORK, March 3, 2021 /PRNewswire/ --  atai Life Sciences  ("atai" or the "Company"), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D
Press Release
Perception Neuroscience's PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced positive data from its first Phase 1 clinical study demonstrating the safety
Press Release
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD
ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ --   Bionomics Limited (ASX: BNO,OTCQB: BNOEF , Germany: AU000000BNO5) ( Bionomics ) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc ( EmpathBio) , a wholly owned subsidiary of Germany-based CNS clinical
Displaying 85 - 90 of 105